Type 1 diabetes (T1D) is a major public health concern, and its incidence and prevalence are increasing worldwide. In the US, ~ 1.25 million people are living with the disease, and that number is expected to increase to ~ 5 million by 2050. T1D patients requires life-long management with daily glucose monitoring and insulin injections that do not fully control the broad range of long-term negative health effects that can include heart disease, nerve damage, and blindness. Given the prevalence, severity, and cost of T1D, researchers and doctors have long sought a more effective treatment or cure, without much success.
Tianhe has developed a novel globally-patented Stem Cell Educator (SCE) technology designed to reverse the autoimmune response in Type 1 diabetes (T1D), Alopecia Areata and other autoimmune diseases. Previous multi-center international clinical studies in more than 100 diabetic patients (aged 3 to 56 years old) with T1D, demonstrated that SCE therapy has shown lasting reversal in autoimmunity in T1D patients, including improved C-peptide levels (an indicator for insulin production from islet b cells), reduced median glycated hemoglobin A1C (HbA1C) values, and decreased median daily usage of insulin, with long-lasting (4 years) clincial effects. These data highlight the SCE therapy may provide the unmet medical need for the treatment of T1D. It has been recognized as one of the top-10-leading technologies for the practical cure of T1D, reported by Juvenile Diabetes Cure Alliance (JDCA, New Yok). Currently, this FDA-approved Phase 2 clinical study will be performed at Hackensack University Medical Center (Hackensack, NJ). For more information, please contact info@TianheCell.com